Valeant Pharmaceuticals International (NYSE:VRX) Rating
Research professionals at Rodman & Renshaw have $118.00 TP on Valeant Pharmaceuticals International (NYSE:VRX). Rodman & Renshaw’s TP means a potential upside of 251.82% from the company’s current price. The rating was shown in a note on Wednesday morning.
Out of 20 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 13 rate it “Buy”, 1 “Sell”, while 8 “Hold”. This means 59% are positive. $213 is the highest target while $70 is the lowest. The $137.65 average target is 407.20% above today’s ($33.6) stock price. Valeant Pharmaceuticals Intl was the topic in 53 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Piper Jaffray downgraded the stock on March 15 to “Underweight” rating. Susquehanna reinitiated it with “Neutral” rating and $105.0 target price in a January 6 report. Canaccord Genuity downgraded the shares of VRX in a report on March 2 to “Hold” rating. RBC Capital Markets maintained the firm’s rating on December 14. RBC Capital Markets has “Outperform” rating and $194 price target. Finally, Rodman & Renshaw initiated the stock with “Buy” rating in a February 16 report.
About 54.05 million shares traded hands or 246.70% up from the average. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 86.44% since August 10, 2015 and is downtrending. It has underperformed by 82.25% the S&P500.
The institutional sentiment decreased to 0.83 in 2015 Q3. Its down 0.10, from 0.93 in 2015Q2. The ratio worsened, as 105 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 198 reduced positions. 63 funds bought stakes while 188 increased positions. They now own 292.15 million shares or 1.71% more from 287.23 million shares in 2015Q2.
Brave Warrior Advisors Llc holds 31.62% of its portfolio in Valeant Pharmaceuticals Intl Inc for 5.58 million shares. Ruane Cunniff & Goldfarb Inc owns 33.92 million shares or 31.06% of their US portfolio. Moreover, Levasseur Capital Partners Llc has 29.76% invested in the company for 162,394 shares. The New York-based Farley Capital Ii L.P. has invested 27.18% in the stock. Pershing Square Capital Management L.P., a New York-based fund reported 19.47 million shares.
Since May 6, 2015, the stock had 1 insider purchase, and 0 selling transactions for $272,395 net activity. Farmer Ronald Harold bought 1,500 shares worth $272,395. Ubben Jeffrey W sold 4.20M shares worth $925.01 million. Mirovsky Pavel sold 38,000 shares worth $9.04 million. Chai-Onn Robert Roswell sold 90,938 shares worth $20.24M.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The company has a market cap of $5.60 billion. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. It currently has negative earnings. The Firm operates through two divisions: developed markets and emerging markets.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Valeant Pharmaceuticals International - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.